Finally, reduced TRPA1 expression in patients treated with either LFN or ADA is accompanied by reduction of the circulating PMN population and decreased activation of CD14+ cells, thus resulting in decreased pain and disability in RA. Here, CD14 is linked to rheumatoid arthritis.